BioSpace News Archive

Kazia Therapeutics Limited is pleased to announce that data from an ongoing Phase II study of paxalisib, an investigational drug for the treatment of diffuse intrinsic pontine glioma and other diffuse midline gliomas, sponsored by the Pacific Pediatric Neuro-Oncology Consortium, has been awarded a late breaking oral presentation at the 2023 Society for Neuro-Oncology Annual Meeting.

Thymmune Therapeutics announced that the U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health has awarded up to $37 million in funding to the Thymus Rejuvenation project.

Theralase® Technologies Inc. is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds, their associated drug formulations and the light systems that activate them.

AbbVie announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax plus dexamethasone for patients with t-positive relapsed or refractory multiple myeloma who have received two or more prior treatments.

Structure Therapeutics Inc. announced positive results from the Phase 1b multiple ascending dose study of its highly selective oral GLP-1 receptor agonist, GSBR-1290, in healthy overweight or obese individuals.

Capricor Therapeutics announced an update on the Company’s positive Type-B clinical meeting with the U.S. Food and Drug Administration on the design and execution of HOPE-3, Capricor’s pivotal Phase 3 trial with lead asset CAP-1002 in treating Duchenne muscular dystrophy.

JCR Pharmaceuticals Co., Ltd. announced key results from the 52-week interim data of its global phase I/II study with JR-171 in individuals with mucopolysaccharidosis type I.

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, will release its third quarter 2023 financial results before the market opens on Friday, October 27, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.

Faeth Therapeutics, a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.

Lexaria Bioscience Corp. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock in a registered direct offering.